Avilex Pharma

Avilex Pharma is a Danish biotech company founded in 2012 by Prof. Strømgaard and Assist. Prof. Bach from University of Copenhagen. Avilex Pharma aims to develop efficacious and safe drugs for the treatment of ischemic stroke, a leading cause of death and disability. The lead candidate – UCCB01-144 –targets the intracellular scaffolding protein, postsynaptic density protein 95 (PSD- 95), which bridges the glutamate receptor subtype, the N-methyl-D-aspartate (NMDA) receptor and neuronal nitric oxide synthase (nNOS). The specific design of UCCB01-144 provides several key advantages such as exceptionally high affinity to PSD-95, increased stability and enhanced in vivo neuroprotective properties and UCCB01-144 is a preclinical lead candidate for the treatment of ischemic stroke.